Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
ADVM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.52 - $14.82
Previous CloseN/A
Volume79.70K
Average Volume (3M)186.84K
Market Cap
$104.84M
Enterprise Value$66.57M
Total Cash (Recent Filing)$154.95M
Total Debt (Recent Filing)$31.19M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 08, 2025EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding20,802,464
10 Day Avg. Volume146,970
30 Day Avg. Volume186,842
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)106.09
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.49
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$30.00Price Target Upside495.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Adverum Biotechnologies News
PremiumCompany Announcements
Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials
---
Bulls Say, Bears Say
Bulls Say
Product PotentialAnalyst maintains an outperform rating on ADVM due to a bullish view on ixo-vec representing a best-in-class product and a potential global sales opportunity exceeding $2 billion.
Safety And EfficacyThe new data for ixo-vec, a gene therapy candidate, is considered very robust on both safety and efficacy, supporting its best-in-class profile.
Bears Say
Cost ImpactThe price target has been adjusted from $20 to $16 due to the assumed cost of the newly disclosed first Phase 3 study and current cash considerations.
Financial ConcernsThere is a major stock overhang due to management not solving how the Phase 3 ixo-vec program will be funded.
---
Ownership Overview
22.11% Insiders
13.38% Mutual Funds
0.40% Other Institutional Investors
53.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADVM FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest stock price was $3.52 and its highest was $14.81 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Adverum Biotechnologies’s market cap is $104.84M.
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Adverum Biotechnologies’s earnings last quarter?
Currently, no data Available
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -1.36.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,802,464 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Currently, no hedge funds are holding shares in ADVM
---
Adverum Biotechnologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (495.24% Upside)
$30.00 (495.24% Upside)
Blogger Sentiment
Bullish
ADVM Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.38%
12-Months-Change
Fundamentals
Return on Equity
-76.26%
Trailing 12-Months
Asset Growth
19.11%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
---
ADVM Stock 12 Month Forecast
Average Price Target
$30.00
▲(495.24% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ADVM
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-38.99%
reiterated a buy rating 4 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -38.99% per trade.
---